Study of a new imaging agent for knee osteoarthritis
This trial tests a special dye (89Zr-Oxine-NCR100) that helps doctors see how cells move in the body. It is for people with moderate knee osteoarthritis to better understand the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 70 years old.
- You have knee osteoarthritis diagnosed by a doctor, with pain lasting more than 6 months.
- Your knee arthritis is grade II or III (moderate), and your pain and function score is between 60 and 180.
- You are not planning to have children and have not had stem cell therapy or knee surgery before.
- You have not used certain arthritis medications or injections in the past 4–12 weeks.
- Your body mass index (BMI) is below 30, and you have no serious infections, heart disease, or metal implants that prevent MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new stem cell treatment (NCR100) for knee osteoarthritis. It aims to see if the injection can reduce pain and improve knee function in people with moderate knee OA.
This trial studies ICM-203, a new treatment, to see if it is safe and if it can help symptoms in people with knee osteoarthritis. It mainly looks at safety and early signs of benefit for knee pain and function.
This study tests a new antibody drug (FB1003) for people with knee osteoarthritis pain. It will check if the drug is safe and helps reduce pain. You may be eligible if you have moderate to severe knee pain and are willing to temporarily stop your usual pain medications.
This study tests a new investigational medicine injected into the knee to see if it is safe and tolerable for people with painful knee osteoarthritis. It may help reduce pain and improve knee function.
This trial tests a new type of knee injection called CCoat for people with mild to moderate knee osteoarthritis. The goal is to see if it helps reduce pain, stiffness, and joint symptoms.
This trial tests an injectable medication called RAB001 for people with knee osteoarthritis that hasn't improved with other treatments. The goal is to see if it's safe and helps reduce pain.
Hear when a new KOA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.